We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Ancora Founder Peter Seeberger Receives Claude S. Hudson Award in Carbohydrate Chemistry
News

Ancora Founder Peter Seeberger Receives Claude S. Hudson Award in Carbohydrate Chemistry

Ancora Founder Peter Seeberger Receives Claude S. Hudson Award in Carbohydrate Chemistry
News

Ancora Founder Peter Seeberger Receives Claude S. Hudson Award in Carbohydrate Chemistry

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ancora Founder Peter Seeberger Receives Claude S. Hudson Award in Carbohydrate Chemistry"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ancora Pharmaceuticals co-founder and scientific advisor Peter Seeberger has been awarded the “Claude S. Hudson Award in Carbohydrate Chemistry” for his development of an automated carbohydrate synthesizer.

Seeberger accepted the award, along with presenting his paper on the research, CARB 004, at the National Meeting of the American Chemical Society being held in Salt Lake City this week.

Seeberger spoke at the meeting, reporting a major advance in creating carbohydrate-based vaccines. “Instead of years, the carbohydrates that may form the basis of revolutionary new vaccines and drugs to battle diseases such as malaria, HIV, neurological and cardiovascular diseases, now can be precisely synthesized to scale in a fraction of that time,” he said. “Ancora’s automated synthesizer is now one of the fastest methods to create complex carbohydrates.”

Ancora Pharmaceuticals, in collaboration with Prof. Seeberger’s lab at the Max Planck Institute in Berlin, is using the carbohydrate synthesizer to discover and develop over a dozen vaccine candidates targeting some of today’s most serious antibiotic resistant infectious diseases. The most advanced candidate, a malaria vaccine, is in late-stage preclinical development and is headed for clinical trials by 2011.
Advertisement